<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Kazan medical journal</journal-id><journal-title-group><journal-title xml:lang="en">Kazan medical journal</journal-title><trans-title-group xml:lang="ru"><trans-title>Казанский медицинский журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0368-4814</issn><issn publication-format="electronic">2587-9359</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">2372</article-id><article-id pub-id-type="doi">10.17750/KMJ2016-89</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Reviews</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Обзоры</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Serotonergic mechanisms of regulation of the systemic circulation vessels lumen</article-title><trans-title-group xml:lang="ru"><trans-title>Серотонинергические механизмы регуляции просвета сосудов большого круга кровообращения</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Sveshnikov</surname><given-names>D S</given-names></name><name xml:lang="ru"><surname>Свешников</surname><given-names>Дмитрий Сергеевич</given-names></name></name-alternatives><email>dmsveshnikov@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kuchuk</surname><given-names>A V</given-names></name><name xml:lang="ru"><surname>Кучук</surname><given-names>Андрей Владимирович</given-names></name></name-alternatives><email>dmsveshnikov@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Smirnov</surname><given-names>V M</given-names></name><name xml:lang="ru"><surname>Смирнов</surname><given-names>Виктор Михайлович</given-names></name></name-alternatives><email>dmsveshnikov@gmail.com</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Cherepanova</surname><given-names>G V</given-names></name><name xml:lang="ru"><surname>Черепанова</surname><given-names>Галина Валерьевна</given-names></name></name-alternatives><email>dmsveshnikov@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Medical Institute of Peoples’ Friendship University of Russia</institution></aff><aff><institution xml:lang="ru">Медицинский институт Российского университета дружбы народов</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Russian National Research Medical University</institution></aff><aff><institution xml:lang="ru">Российский национальный исследовательский медицинский университет</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2016-01-15" publication-format="electronic"><day>15</day><month>01</month><year>2016</year></pub-date><volume>97</volume><issue>1</issue><issue-title xml:lang="en">VOL 97, NO1 (2016)</issue-title><issue-title xml:lang="ru">ТОМ 97, №1 (2016)</issue-title><fpage>89</fpage><lpage>94</lpage><history><date date-type="received" iso-8601-date="2016-03-28"><day>28</day><month>03</month><year>2016</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2016, Sveshnikov D.S., Kuchuk A.V., Smirnov V.M., Cherepanova G.V.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2016, Свешников Д.С., Кучук А.В., Смирнов В.М., Черепанова Г.В.</copyright-statement><copyright-year>2016</copyright-year><copyright-holder xml:lang="en">Sveshnikov D.S., Kuchuk A.V., Smirnov V.M., Cherepanova G.V.</copyright-holder><copyright-holder xml:lang="ru">Свешников Д.С., Кучук А.В., Смирнов В.М., Черепанова Г.В.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">http://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://kazanmedjournal.ru/kazanmedj/article/view/2372">https://kazanmedjournal.ru/kazanmedj/article/view/2372</self-uri><abstract xml:lang="en"><p>Review is devoted to the assessment of the serotonergic mechanisms role in the hemodynamics regulation. The special attention is given to the role of various serotonin receptors involved in the gastrointestinal tract motility regulation, in particular located in the digestive system vessel walls. It is known that serotonin has a dual effect on the vessel lumen, due to the heterogeneity of serotonin receptors, which are part of the vascular wall, and different sensitivity of serotonin receptors. Mechanisms at various levels, from central to local, are able to participate in the serotonergic regulation of the vascular lumen, as well as in motility control. According to our data, in the regulation of the upper gastrointestinal tract motor activity participate 5-HT1B- and 5-HT3-receptors located in the stomach and intestines autonomic ganglia, 5-HT2B-receptors localized on stomach plexus neurons and on small and large intestine smooth muscles; 5-HT4-receptors located on stomach wall smooth muscles and intraorgan intestinal plexus neurons. According to the literature, vascular wall 5-HT2B- and 5-HT7-receptors provide vasodilation, whereas the 5-HT1B/1D-, 5-HT2A- and 5-HT2B-receptors - vasoconstriction. Significance of plasma free serotonin level for hemodynamic, serotonergic mechanisms for the different types vessels diameter changing, the interaction of serotonin receptors with sympathetic nervous system and their possible role in the vascular tone regulation are described, particularly the role of presynaptic 5-HT1B/1D-receptors, which prevent the catecholamines release by vegetative nerves endings, is established. Different points of view on the serotoninergic regulation issue, existing contradictions, as well as areas for further fundamental and practical research are presented.</p></abstract><trans-abstract xml:lang="ru"><p>Обзор посвящён оценке роли серотонинергических механизмов в регуляции гемодинамики. Основное внимание уделено роли различных серотониновых рецепторов, принимающих участие в регуляции моторики желудочно-кишечного тракта, в частности расположенных в стенках сосудов органов пищеварительной системы. Известно, что серотонин обладает двояким воздействием на просвет сосуда, что обусловлено как гетерогенностью серотониновых рецепторов, входящих в состав сосудистой стенки, так и различной чувствительностью рецепторов к серотонину. В серотонинергической регуляции просвета сосудов, как и регуляции моторики, способны принимать участие механизмы различных уровней: от центрального до местного. По нашим данным, в регуляции моторной активности верхних отделов пищеварительного канала принимают участие 5-HT1b- и 5-HT3-рецепторы, расположенные на вегетативных ганглиях желудка и кишечника, 5-HT2b-рецепторы, локализующиеся на нейронах сплетений желудка, а также на гладких мышцах тонкой и толстой кишки; 5-HT4-рецепторы, расположенные на гладких мышцах желудочной стенки и нейронах внутриорганных кишечных сплетений. По данным литературы, 5-НТ2В- и 5-НТ7-рецепторы сосудистой стенки обеспечивают вазодилатацию, тогда как 5-HT1B/1D-, 5-HT2A- и 5-HT2B-рецепторы - вазоконстрикцию. Описаны значение свободного серотонина плазмы крови для гемодинамики, серотонинергические механизмы изменения диаметра сосудов различных типов, взаимодействие серотониновых рецепторов с симпатической нервной системой и их возможная роль в регуляции сосудистого тонуса, в частности установлена роль пресинаптических 5-HT1B/1D-рецепторов, предотвращающих выделение катехоламинов вегетативными окончаниями. Представлены различные точки зрения на проблему серотонинергической регуляции, существующие противоречия, а также направления для дальнейших фундаментальных и практических исследований.</p></trans-abstract><kwd-group xml:lang="en"><kwd>serotonin</kwd><kwd>visceral circulation</kwd><kwd>5-HT-receptors</kwd><kwd>regulation</kwd><kwd>mechanisms</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>серотонин</kwd><kwd>висцеральное кровообращение</kwd><kwd>5-HT-рецепторы</kwd><kwd>регуляция</kwd><kwd>механизмы</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Ахметзянов В.Ф., Латфуллин И.А., Нигматуллина Р.Р. Современные представления о роли серотонинергической системы в регуляции сердечно-сосудистой деятельности в норме и патологии. Казанский мед. ж. 2006; 87 (2): 110-121.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Нигматуллина Р.Р., Кириллова В.В., Джорджикия Р.К. и др. Концентрация серотонина в крови и тромбоцитах у пациентов с ХСН. Ж. сердечн. недостат. 2008; 9 (6): 289-291.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Свешников Д.С., Смирнов В.М., Мясников И.Л., Кучук А.В. Исследование природы нервных волокон симпатического ствола, вызывающих усиление сокращений желудка. Бюлл. эксперим. биол. и мед. 2011; 152 (9): 249-252.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Свешников Д.С., Торшин В.И., Смирнов В.М. и др. Значение различных серотониновых рецепторов в регуляции моторики желудочно-кишечного тракта. Патол. физиол. и эксперим. терап. 2014; (3): 45-51.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Barnes N., Andrade R., Bockaert J. et al. 5-Hydroxytryptamine receptors, introduction. IUPHAR/BPS Guide to Pharmacology. Last modified on 19/11/2014. http://www.guidetopharmacology.org/GRAC/FamilyIntroductionForward?familyId=1 (access date: 12.06.2015).</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Bhaskaran S., Zaluski J., Banes-Berceli A. Molecular interactions of serotonin (5-HT) and endothelin-1 in vascular smooth muscle cells: in vitro and ex vivo analyses. Am. J. Physiol. Cell Physiol. 2014; 306 (2): 143-151. http://dx.doi.org/10.1152/ajpcell.00247.2013</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Brenner B., Harney J.T., Ahmed B.A. et al. Plasma serotonin levels and the platelet serotonin transporter. J. Neurochem. 2007; (102): 206-215. http://dx.doi.org/10.1111/j.1471-4159.2007.04542.x</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Centurion D., Glusa E., Sanchez-Lopez A. et al. 5-HT7, but not 5-HT2B, receptors mediate hypotension in vagosympathetctomized rats. Eur. J. Pharmacol. 2004; (502): 239-242. http://dx.doi.org/10.1016/j.ejphar.2004.08.050</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Cohen M.L., Fuller R.W., Kurz K.D. LY53857, a selective and potent serotonergic (5-HT2) receptor antagonist, does not lower blood pressure in the spontaneously hypertensive rat. J. Pharmacol. Exp. Ther. 1983; (227): 327-332.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Dalton D.W., Feniuk W., Humphrey P.P. An investigation into the mechanisms of the cardiovascular effects of 5-hydroxytryptamine in conscious normotensive and DOCA-salt hypertensive rats. J. Auton. Pharmacol. 1996; (6): 219-228.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Darios E.S., Barman S.M., Orer H.S. et al. 5-Hydroxytryptamine does not reduce sympathetic nerve activity or neuroeffector function in the splanchnic circulation. Eur. J. Pharmacol. 2015; (5): 140-147. http://dx.doi.org/10.1016/j.ejphar.2015.02.032</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Diaz J., Ni W., King A. et al. 5-Hydroxytryptamine lowers blood pressure in normotensive and hypertensive rats. J. Pharmacol. Exp. Ther. 2008; (325): 1031-1038. http://dx.doi.org/10.1124/jpet.108.136226</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Dong J.S., Hyun J.N., Jae G.K. et al. Serotonin contracts the rat mesenteric artery by inhibiting 4-aminopyridine-sensitive Kv channels via the 5-HT2A receptor and Src tyrosine kinase. Experim. Mol. Med. 2013; (45): 1-10.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Dorn S.D., Morris C.B., Hu Y. Irritable bowel syndrome subtypes defined by Rome II and Rome III criteria are similar. J. Clin. Gastroenterol. 2009; (43): 214-220. http://dx.doi.org/10.1097/MCG.0b013e31815bd749</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Gaddum J.H., Picarelli Z.P. Two kinds of tryptamine receptor. Br. J. Pharmacol. 1957; (12): 323-328. http://dx.doi.org/10.1111/j.1476-5381.1957.tb00142.x</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Gershon M.D. 5-Hydroxytryptamine (serotonin) in the gastrointestinal tract. Curr. Opin. Endocrinol. Diabetes Obes. 2013; 20 (1): 14-21. http://dx.doi.org/10.1097/MED.0b013e32835bc703</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Gershon M.D., Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology. 2007; 132 (1): 397-414. http://dx.doi.org/10.1053/j.gastro.2006.11.002</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Gothert M., Molderings G.J., Fink K., Schlicker E. Heterogeneity of presynaptic serotonin receptors on sympathetic neurons in blood vessels. Blood Vessels. 1991; (28): 11-18.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Gradin K., Pettersson A., Hedner T., Persson B. Chronic 5-HT2 receptor blockade with ritanserin does not reduce blood pressure in the spontaneously hypertensive rat. J. Neural. Transm. 1985; (64): 145-149. http://dx.doi.org/10.1007/BF01245975</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Kawasaki H., Takasaki K. Vasoconstrictor response induced by 5-hydroxytryptamine released from vascular adrenergic nerves by periarterial nerve stimulation. J. Pharmacol. Exp. Ther. 1984; (229): 816-822. http://dx.doi.org/10.1111/j.1440-1681.2011.05504.x</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Linder A.E., Davis R.P., Burnett R., Watts S. Function of the serotonin transporter in vasculature of the female rat: comparison with the male. Clin. Exp. Pharmacol. Physiol. 2011; 38 (5): 314-322.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Machida T., Iizuka K., Hirafuji M. Recent advances in 5-hydroxytryptamine (5-HT) receptor research: how many pathophysiological roles does 5-HT play via its multiple receptor subtypes? Biol. Pharm. Bull. 2013; 36 (9): 1416-1419. http://dx.doi.org/10.1248/bpb.b13-00344</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Moreno L., Martinez-Cuesta M.A., Pique J.M. et. al. Anatomical differences in responsiveness to vasoconstrictors in the mesenteric veins from normal and portal hypertensive rats. Naunyn Schmiedebergs Arch. Pharmacol. 1996; (354): 474-480. http://dx.doi.org/10.1007/BF00168439</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Ni W., Geddes T.J., Priestley J.R. et al. The existence of a local 5-hydroxytryptaminergic system in peripheral arteries. Br. J. Pharmacol. 2008; (154): 663-674. http://dx.doi.org/10.1038/bjp.2008.111</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Ni W., Thompson J., Northcott C. et al. The serotonin transporter is present and functional in peripheral arterial smooth muscle. J. Cardiovasc. Pharmacol. 2004; (43): 770-781. http://dx.doi.org/10.1097/00005344-200406000-00006</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Russell A., Banes A., Berlin H. et al. 5-Hydroxytryptamine 2B receptor function is enhanced in the N-nitro-L-arginine hypertensive rat. J. Pharmacol. Exp. Ther. 2002; (303): 179-187. http://dx.doi.org/10.1124/jpet.102.037390</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Terron J.A., Sanchez-Maldonado C., Martinez-Garcia E. Pharmacological evidence that 5-HT1B/1D receptors mediate hypotension in anesthetized rats. Eur. J. Pharmacol. 2007; (576): 132-135. http://dx.doi.org/10.1016/j.ejphar.2007.08.005</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Van Zwieten P.A., Blauw G.F., van Brummelen P. Serotonergic receptors and drugs in hypertension. Pharmacol. Toxicol. 1992; (70): 17-22. http://dx.doi.org/10.1111/j.1600-0773.1992.tb01617.x</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Watts S.W., Davis R.P. 5-Hydroxtryptamine receptors in systemic hypertension: an arterial focus. Cardiovasc. Ther. 2011; 29 (1): 54-67. http://dx.doi.org/10.1111/j.1755-5922.2010.00173.x</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Watts S.W., Darios E.S., Seitz B.M., Thompson J.M. 5-HT is a potent relaxant in rat superior mesenteric veins. Pharmacol. Res. Perspect. 2015; 3 (1): e00103. doi: 10.1002/ prp2.103. Epub 2015 Jan. 5.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Watts S.W., Baez M., Webb R.C. The 5-hydroxytryptamine 2B receptor and 5-HT receptor signal transduction in mesenteric arteries from deoxycorticosterone acetate-salt hypertension. J. Pharmacol. Exp. Ther. 1996; (277): 1103-1113.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Wouters M.M., Farrugia G., Schemann M. 5-HT receptors on interstitial cells of Cajal, smooth muscle and enteric nerves. Neurogastroenterol. Motil. 2007; 19 (2): 5-12. http://dx.doi.org/10.1111/j.1365-2982.2007.00963.x</mixed-citation></ref></ref-list></back></article>
